Celgene (CELG) EPS & PE Ratio History

Current and historical earning per share (EPS) and price to earnings (PE) ratio for Celgene (CELG) over the last 10 years. The current PE ratio for Celgene as of November 21, 2017 is 16.33.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $82.275B $11.229B
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.